Despite a long-term downtrend since December 2021, Pfizer's stock may still be undervalued The company is now aiming to establish a stable, growth-oriented model following a year...
U.S. jobs report, ISM PMI surveys, more earnings in focus. Apple shares are a buy with fiscal Q3 results due on Thursday. Pfizer’s stock is set to struggle amid shrinking...
Earnings season continues, with healthcare companies set to report next week Among them is Pfizer, whose stock has corrected significantly of late Based on the company's strong...
Stocks on Wall Street extended their bull market rally this week despite hawkish signals from the Fed. Investors are still fighting the Fed as Powell warned July meeting is...
Stagflation remains one of the primary risks for the global economy in 2023. The stock market’s trajectory will continue to be dictated by worries over persistently high...
Drugmaker Merck's (NYSE:MRK) stock has outperformed its competitors year to date (ytd), rising 30.6%. Pfizer (NYSE:PFE), which I am bearish on, is down 16.9% so far this year. The...
Pfizer (NYSE:PFE) faces a $16 to $18 billion loss in revenue from 2025 through 2030 as it loses essential patents on five drugs.The drugs account for 40% of the company's Q3...
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highs Both Iran, US likely looking...